First QuickMIC[®] agreement signed for clinical routine use in Italy
The diagnostics company Gradientech announces the successful implementation of the QuickMIC® system for ultra-rapid antibiotic susceptibility testing (AST) into clinical routine use at the Molinette Hospital in Turin, Italy.
The Molinette Hospital is as part of the Azienda Ospedaliero Universitaria (AOU) Città della Salute e della Scienza di Torino, one of the biggest university hospitals in Italy and in Europe, with a mission to provide excellent patient care and conduct top-tier research.
"After a successful evaluation of the QuickMIC system, we are now prepared to implement it in our clinical routine. I am very proud to provide our clinicians with the fastest AST system available on the market. Rapid and accurate AST results are crucial for determining the appropriate treatment for severe infections in critically ill patients," says Prof.ssa Cristina Costa, Director of the Clinical Microbiology Laboratory at the AOU Città della Salute e della Scienza hospital.
a.d.a SRL is exclusively distributing the QuickMIC system in Italy. “We are proud to introduce QuickMIC to the Italian market and the response received from hospitals is encouraging. The innovative technology of QuickMIC, which delivers precise and accurate minimum inhibitory concentration (MIC) results in just 2 to 4 hours, is attractive. Rapid, precise and accurate results are crucial for confirming and adjusting antimicrobial treatments, guiding optimal clinical decisions, and combating antimicrobial resistance, ”says Andrea Grillo, Managing Director and Pietro Lombardi, Scientific Director of a.d.a. SRL.
The ultra-rapid and precise antibiotic susceptibility testing results of QuickMIC® contribute to timely and effective management of sepsis patients, helping clinicians make faster antibiotic treatment decisions. Its modular design offers affordable scaling possibilities, making QuickMIC suitable for both small and large hospital laboratories. QuickMIC and its gram-negative panel are CE marked and commercially available in Europe but not yet available for sale in the United States.
For further information, please contact:
Sara Thorslund, PhD, CEO
Tel: +46 736 29 35 80
sara.thorslund@gradientech.se
About Gradientech
Gradientech is a leader in ultra-rapid antibiotic susceptibility testing, developing next-generation diagnostics for infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, contributes to the effective management of sepsis patients by supporting antibiotic treatment decisions in record time. This helps save lives, reduce healthcare costs, and combat the spread of antibiotic resistance - one of our greatest global health threats. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.
